In vitro cytotoxicity assay to evaluate the toxicity of an electrophilic reactive metabolite using glutathione-depleted rat primary cultured hepatocytes

Chemico-Biological Interactions

Volumn 188, Issue 3, 2010, Pages 404-411

  Fujimoto, Kazunori ^a   Kishino, Hiroyuki ^a   Yamoto, Takashi ^a   Manabe, Sunao ^a   Sanbuissho, Atsushi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Cellular glutathione depletion; Cytotoxic sensitivity gap; Electrophilic reactive metabolite; Idiosyncratic drug toxicity; Rat primary cultured hepatocyte

Indexed keywords

AMINOPHENAZONE; AMLODIPINE; AMODIAQUINE; ATORVASTATIN; BENZBROMARONE; BUTHIONINE SULFOXIMINE; CAFFEINE; CARBAMAZEPINE; CELECOXIB; CLOPIDOGREL; CLOZAPINE; DICLOFENAC; DONEPEZIL; ERYTHROMYCIN; ETHINYLESTRADIOL; FLUOXETINE; FLUTAMIDE; FUROSEMIDE; GLUTATHIONE; IMIPRAMINE; INDOMETACIN; LEVOFLOXACIN; NEVIRAPINE; OLANZAPINE; OLMESARTAN; PARACETAMOL; PHENYTOIN; PIOGLITAZONE; PRAVASTATIN; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG CLASSIFICATION; DRUG SAFETY; ELECTROPHILICITY; IN VITRO STUDY; LIVER CELL CULTURE; METABOLITE; NONHUMAN; PREDICTION; RAT; RISK FACTOR; SENSITIVITY ANALYSIS;

ACETAMINOPHEN; ANIMALS; BUTHIONINE SULFOXIMINE; CELLS, CULTURED; DRUG APPROVAL; DRUG TOXICITY; GLUTATHIONE; HEPATOCYTES; RATS; RISK; TOXICITY TESTS;

RATTUS;

EID: 78149467148     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.09.012     Document Type: Article

References (28)

1. Knowles S.R., Uetrecht J., Shear N.H. Idiosyncratic drug reactions: the reactive metabolite syndrome. Lancet 2000, 356(2000):1587-1591.
2. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 2005, 4:489-499.
3. Pirmohamed M., Naisbitt D.J., Gordon F., Park B.K. The danger hypothesis - potential role in idiosyncratic drug reactions. Toxicology 2002, 181-182:55-63.
4. Uetrecht J. Screening for the potential of a drug candidate to cause idiosyncratic drug reactions. Drug Discov. Today 2003, 8:832-837.
5. Uetrecht J. Idiosyncratic drug reactions: past, present, and future. Chem. Res. Toxicol. 2008, 21:84-92.
6. Samuel K., Yin W., Stearns R.A., Tang Y.S., Chaudhary A.G., Jewell J.P., Lanza T., Lin L.S., Hagmann W.K., Evans D.C., Kumar S. Addressing the metabolic activation potential of new leads in drug discovery: a case study using ion trap mass spectrometry and tritium labeling techniques. J. Mass Spectrom. 2003, 38:211-221.
7. Gan J., Harper T.W., Hsueh M.M., Qu Q., Humphreys W.G. Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites. Chem. Res. Toxicol. 2005, 18:896-903.
8. Bauman J.N., Kelly J.M., Tripathy S., Zhao S.X., Lam W.W., Kalgutkar A.S., Obach R.S. Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. Chem. Res. Toxicol. 2009, 22:332-340.
9. Nakayama S., Atsumi R., Takakusa H., Kobayashi Y., Kurihara A., Nagai Y., Nakai D., Okazaki O. A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab. Dispos. 2009, 37:1970-1977.
10. Takakusa H., Masumoto H., Makino C., Okazaki O., Sudo K. Quantitative assessment of reactive metabolite formation using 35S-labeled glutathione. Drug Metab. Pharmacokinet. 2009, 24:100-107.
11. Usui T., Mise M., Hashizume T., Yabuki M., Komuro S. Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. Drug Metab. Dispos. 2009, 37:2383-2392.
12. O'Brien P.J., Irwin W., Diaz D., Howard-Cofield E., Krejsa C.M., Slaughter M.R., Gao B., Kaludercic N., Angeline A., Bernardi P., Brain P., Hougham C. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 2006, 80:580-604.
13. Xu J.J., Henstock P.V., Dunn M.C., Smith A.R., Chabot J.R., de Graaf D. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 2008, 105:97-105.
14. Tukov E.F., Maddox J.F., Amacher D.E., Bobrowski W.F., Roth R.A., Ganey P.E. Modeling inflammation-drug interactions in vitro: a rat Kupffer cell-hepatocyte coculture system. Toxicol. In Vitro 2006, 20:1488-1499.
15. Cosqrove B.D., King B.M., Hasan M.A., Alexopoulos L.G., Farazi P.A., Hendriks B.S., Griffith L.G., Sorger P.K., Tidor B., Xu J.J., Lauffenburger D.A. Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol. Appl. Pharmacol. 2009, 237:317-330.
16. Watanabe T., Sagisaka H., Arakawa S., Shibaya Y., Watanabe M., Igarashi I., Tanaka K., Totsuka S., Takasaki W., Manabe S. A novel model of continuous depletion of glutathione in mice treated with l-buthionine (S,R)-sulfoximine. J. Toxicol. Sci. 2003, 28:455-469.
17. Nishiya T., Mori K., Hattori C., Kai K., Kataoka H., Masubichi N., Jindo T., Manabe S. The crucial protective role of glutathione against tienilic acid hepatotoxicity in rats. Toxicol. Appl. Pharmacol. 2008, 232:280-291.
18. Morita M., Akai S., Hosomi H., Tsuneyama K., Nakajima M., Yokoi T. Drug-induced hepatotoxicity test using g-glutamylcysteine synthetase knockdown rat. Toxicol. Lett. 2009, 189:159-165.
19. Shimizu S., Atsumi R., Itokawa K., Iwasaki M., Aoki T., Ono C., Izumi T., Sudo K., Okazaki O. Metabolism-dependent hepatotoxicity of amodiaquine in glutathione-depleted mice. Arch. Toxicol. 2009, 83:701-707.
20. Li A.P. Metabolism comparative cytotoxicity assay (MCCA) and cytotoxic metabolic pathway identification assay (CMPIA) with cryopreserved human hepatocytes for the evaluation of metabolism-based cytotoxicity in vitro: proof-of-concept study with aflatoxin B1. Chem. Biol. Interact. 2009, 179:4-8.
21. James L.P., Mayeux P.R., Hinson J.A. Acetaminophen-induced hepatotoxicity. Drug Metab. Dispos. 2003, 31:1499-1506.
22. Kocarek T.A., Schuetz E.G., Guzelian P.S. Expression of multiple forms of cytochrome P450 mRNAs in primary cultures of rat hepatocytes maintained on matrigel. Mol. Pharmacol. 1992, 43:328-334.
23. Manier J.W., Chang W.W., Kirchner J.P., Beltaos E. Hepatotoxicity associated with ticrynafen - a uricosuric diuretic. Am. J. Gastroenterol. 1982, 77:401-404.
24. Tesfa D., Keisu M., Palmblad J. Idiosyncratic drug-induced agranulocytosis: Possible mechanisms and management. Am. J. Hematol. 2009, 84:428-434.
25. Shi E.C., Fisher R., McEvoy M., Vantol R., Rose M., Ham J.M., McEvoy M., Vantol R., Rose M., Ham J.M. Factors influencing hepatic glutathione concentrations: a study in surgical patients. Clin. Sci. (Lond.) 1982, 62:279-283.
26. Higashi T., Furukawa M., Hikita K., Naruse A., Tateishi N., Sakamoto Y. Re-evaluation of protein-bound glutathione in rat liver. J. Biochem. 1985, 98:1661-1667.
27. Kato R., Yasumori T. Comparative studies on pharmacokinetics and toxicokinetics parameters between the human clinical dose and animal nontoxic dose in new drug development. Jpn. J. Clin. Pharmacol. Ther. 1996, 27:759-769. (in Japanese).
28. Baker D.D., Laskin O., Latriano L., Amin R., Lapinskas P. Comparison of the effect of GSH depletion in multiple species and the effect on reactive metabolite cytotoxicity. The Toxicologist 2009, 108:87.